Compare RENX & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RENX | ADVB |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | 38 | 31 |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 6.2M |
| IPO Year | N/A | N/A |
| Metric | RENX | ADVB |
|---|---|---|
| Price | $2.05 | $7.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 527.8K | 314.9K |
| Earning Date | 05-22-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.19 |
| 52 Week High | $3.48 | $7.59 |
| Indicator | RENX | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 46.85 | 67.18 |
| Support Level | $0.12 | $0.33 |
| Resistance Level | $3.15 | $7.59 |
| Average True Range (ATR) | 0.23 | 0.80 |
| MACD | -0.11 | 0.04 |
| Stochastic Oscillator | 28.95 | 89.66 |
RenX Enterprises Corp is engaged in real property development using purpose-built, prefabricated modules constructed from both wood and steel. The Company's operations mainly focused on the acquisition, entitlement, and development of residential properties in high-growth markets across the United States. These efforts included the direct acquisition of land, strategic investments in real estate entities, and joint venture partnerships targeting green, single-family, and multifamily housing projects. The company operates into four segments as of December 31, 2025: real estate development, technology, compost sales, and logistics.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.